Manal M. Hassan
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (8)
Supplementary Table S5 shows results of univariate analysis for 77 chronically elevated serum alanine aminotransferase (cALT)-defined nonalcoholic fatty liver disease in the Pancreatic Cancer Case-Control Consortium (PanC4) data
Year:
2025
Supplementary Table S1 shows results of univariate analysis for 77 chronically elevated serum alanine aminotransferase (cALT)-defined nonalcoholic fatty liver disease SNPs in the Pancreatic Cancer Cohort Consortium (PanScan) data
Year:
2025
Supplementary Table S5 shows results of univariate analysis for 77 chronically elevated serum alanine aminotransferase (cALT)-defined nonalcoholic fatty liver disease in the Pancreatic Cancer Case-Control Consortium (PanC4) data
Year:
2024
Supplementary Table S5 shows results of univariate analysis for 77 chronically elevated serum alanine aminotransferase (cALT)-defined nonalcoholic fatty liver disease in the Pancreatic Cancer Case-Control Consortium (PanC4) data
Year:
2024
Background: There are conflicting data on whether nonalcoholic fatty liver disease (NAFLD) is associated with susceptibility to pancreatic cancer (PC). Using Mendelian randomization (MR), we investigated the relationship between genetic predisposition to NAFLD and risk for PC. Methods: Data from genome-wide association studies within the Pancreatic Cancer Cohort Consortium (PanScan; cases n=5090, controls n=8733) and the Pancreatic Cancer Case Control Consortium (PanC4; cases n=4,163, controls n=3,792) were analyzed. We used data on 68 genetic variants with four different MR methods (inverse variance weighting [IVW], MR-Egger, simple median, and penalized weighted median) separately to predict genetic heritability of NAFLD. We then assessed the relationship between each of the four MR methods and PC risk, using logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs), adjusting for PC risk factors, including obesity and diabetes. Results: No association was found between genetically predicted NAFLD and PC risk in the PanScan or PanC4 samples (e.g., PanScan, IVW OR=1.04, 95% CI: 0.88-1.22, MR-Egger OR=0.89, 95% CI: 0.65-1.21; PanC4, IVW OR=1.07, 95% CI: 0.90-1.27, MR-Egger OR=0.93, 95% CI: 0.67-1.28). None of the four MR methods indicated an association between genetically predicted NAFLD and PC risk in either sample. Conclusions: Genetic predisposition to NAFLD is not associated with PC risk. Impact: Given the close relationship between NAFLD and metabolic conditions, it is plausible that any association between NAFLD and PC might reflect host metabolic perturbations (e.g., obesity, diabetes, or metabolic syndrome) and does not necessarily reflect a causal relationship between NAFLD and PC.
Year:
2024
Supplementary Table S1 shows results of univariate analysis for 77 chronically elevated serum alanine aminotransferase (cALT)-defined nonalcoholic fatty liver disease SNPs in the Pancreatic Cancer Cohort Consortium (PanScan) data
Year:
2024
Supplementary Table S1 shows results of univariate analysis for 77 chronically elevated serum alanine aminotransferase (cALT)-defined nonalcoholic fatty liver disease SNPs in the Pancreatic Cancer Cohort Consortium (PanScan) data
Year:
2024
Background: It is estimated that 6% to 20% of all cholangiocarcinoma (CCA) diagnoses are explained by primary sclerosing cholangitis (PSC), but the underlying risk factors in the absence of PSC are unclear. We examined associations of different risk factors with intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC) in the United States. Methods: We conducted a case–control study of 121 patients with ECC and 308 patients with ICC treated at MD Anderson Cancer Center between May 2014 and March 2020, compared with 1,061 healthy controls. Multivariable logistic regression analysis was applied to estimate the adjusted OR (AOR) and 95% confidence interval (CI) for each risk factor. Results: Being Asian, diabetes mellitus, family history of cancer, and gallbladder stones were associated with higher odds of developing ICC and ECC. Each 1-unit increase in body mass index in early adulthood (ages 20–40 years) was associated with a decrease in age at diagnosis of CCA (6.7 months, P < 0.001; 6.1 months for ICC, P = 0.001; 8.2 months for ECC, P = 0.007). A family history of cancer was significantly associated with the risk of ICC and ECC development; the AORs (95% CI) were 1.11 (1.06–1.48) and 1.32 (1.01–2.00) for ICC and ECC, respectively. Conclusions: In this study, early adulthood onset of obesity was significantly associated with CCA and may predict early diagnosis at younger age than normal weight individuals. Impact: The study highlights the association between obesity and CCA, independent of PSC. There is a need to consider the mechanistic pathways of obesity in the absence of fatty liver and cirrhosis.
Year:
2023
Collaborators (32)
Rayjean Hung
University of Toronto
Neal Freedman
Branch Chief
National Cancer Institute
Christopher A. Haiman
University of Southern California
Ian M. Thompson
University of Texas Health Science Center at San Antonio
Xiao‐Ou Shu
Vanderbilt University Medical Center
Lynne Wilkens
Professor
University of Hawaii at Manoa
Anne Tjonneland
Professor
Københavns Universitet
Ulrike Peters
Fred Hutchinson Cancer Research Center
Wei Zheng
-
Miquel Porta
-
Peter Kraft
Professor
Harvard T.H. Chan School of Public Health
Kari Rabe
Assistant Professor of Biostatistics
Mayo Clinic
Stephen Chanock
National Institutes of Health
Alison Klein
Professor
-
Federico Canzian
Group Leader
Deutsches Krebsforschungszentrum
Herbert Yu
Researcher/Professor
University of Hawaii at Manoa
Martijn C.G.J. Brouwers
-
Thilo Hackert
University Hospital Heidelberg
Elio Riboli
Professor of Cancer Epidemiology
Imperial College London
Rachael Solomon
Senior Eoidemiologist
Division of Cancer Epidemiology and Genetics, National Cancer Institute
Jean Wactawki-Wende
Dean, Suny Distinguished Professor
University at Buffalo
Malin Sund
Professor/Consultant
University of Helsinki
Loic Le Marchand
Professor
University of Hawaii
Donghui Li
Professor
The University of Texas MD Anderson Cancer Center
Anne Zeleniuch-Jacquotte
Professor of Population Health and Environmental Medicine
NYU School of Medicine
Alan Arslan
Associate Professor
NYU Langone Medical Center
Nuria Malats
Group Leader
Centro Nacional de Investigaciones Oncológicas
Kala Visvanathan
Professor
Johns Hopkins University
Veronica Setiawan
Associate Professor
University of Southern California
Charles Kooperberg
Fred Hutchinson Cancer Research Center
Graham Giles
Head of Research
-
Manolis Kogevinas
Senior Researcher
Barcelona Institute for Global Health
Make your next move.
Prepare your application
Review drafts before you send them.